Lv3
390 积分 2025-08-19 加入
Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial
1小时前
待确认
Survival with Trastuzumab Emtansine in Residual HER2-Positive Breast Cancer
16天前
已完结
Understanding the impact of psychosocial working conditions on workers’ health: we have come a long way, but are we there yet?
24天前
已完结
Survival with Trastuzumab Emtansine in Residual HER2-Positive Breast Cancer
28天前
已关闭
Survival with Trastuzumab Emtansine in Residual HER2-Positive Breast Cancer
28天前
已完结
Trastuzumab deruxtecan in breast cancer
1个月前
已完结
Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer
1个月前
已完结
德曲妥珠单抗临床管理路径及不良反应处理中国专家共识（2024版）
2个月前
已完结
Spatial determinants of antibody-drug conjugate SHR-A1811 efficacy in neoadjuvant treatment for HER2-positive breast cancer
2个月前
已完结
Targeting HER2 heterogeneity in breast and gastrointestinal cancers
2个月前
已完结
皖公网安备34019202002308
